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Abstract
Rising antibiotic resistance among Escherichia coli, the leading cause of urinary tract infections (UTIs), has placed a new
focus on molecular pathogenesis studies, aiming to identify new therapeutic targets. Anti-virulence agents are attractive as
chemotherapeutics to attenuate an organism during disease but not necessarily during benign commensalism, thus
decreasing the stress on beneficial microbial communities and lessening the emergence of resistance. We and others have
demonstrated that the K antigen capsule of E. coli is a preeminent virulence determinant during UTI and more invasive
diseases. Components of assembly and export are highly conserved among the major K antigen capsular types associated
with UTI-causing E. coli and are distinct from the capsule biogenesis machinery of many commensal E. coli, making these
attractive therapeutic targets. We conducted a screen for anti-capsular small molecules and identified an agent designated
‘‘C7’’ that blocks the production of K1 and K5 capsules, unrelated polysaccharide types among the Group 2–3 capsules.
Herein lies proof-of-concept that this screen may be implemented with larger chemical libraries to identify second-
generation small-molecule inhibitors of capsule biogenesis. These inhibitors will lead to a better understanding of capsule
biogenesis and may represent a new class of therapeutics.
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Introduction
Escherichia coli is the leading cause of community-acquired
urinary tract infections (UTIs), producing over 80% of commu-
nity-acquired UTI and at least 50% of nosocomial UTIs [1].
Twenty five to forty percent of first-time community-acquired
UTIs are followed by recurrences caused by the same clone of
UPEC. In addition, E. coli also accounts for a significant
proportion of sepsis and meningitis of the young and old, with
the infections originating from the urinary tract or direct
translocation from the gut into the bloodstream. With over 100
million UTIs occurring annually throughout the world, including
more than 10 million cases in U.S. adolescents and adults (per
NIDDK data, [2]), UPEC accounts for substantial medical costs
and morbidity worldwide.
Accompanying the large use of antibiotics for UTI and other
common infections like those of the respiratory tract has been
rising antibiotic resistance among E. coli, resulting in many cases in
multidrug resistant strains [3,4,5,6,7], and invigorating efforts to
elucidate vulnerable targets in the molecular pathogenesis of
infection. Of the oral therapies for community-acquired UTI,
trimethoprim-sulfamethoxazole (TMP-SMX) has been a mainstay
in outpatient therapy, but resistance to TMP-SMX has recently
emerged among urinary tract isolates with rates in excess of 20%
in some areas (e.g., [8]). The Infectious Diseases Society of
America (IDSA) now recommends that in regions where resistance
to TMP-SMX exceeds 15%, TMP-SMX should no longer be used
for empirical therapy [9]. Ciprofloxacin and other fluoroquino-
lones are used increasingly, but resistance to these agents is also on
the rise (e.g., [3]), and fluoroquinolone-resistant isolates of E. coli
are often multidrug resistant [10]. A common choice for empiric
therapy of acute uncomplicated UTIs is nitrofurantoin; however,
resistance to this antibiotic is also increasing [11], and its use
requires longer treatment courses while being a poor treatment of
outpatients treated for pyelonephritis Much of the resistance arises
from bacteria such as E. coli that also colonize sites separate from
the sites of infection such as the enteric tract. Inhibitors capable of
attenuating an organism during disease but not promoting
resistance among colonizing bacteria are attractive therapeutics
that would bolster the arsenal of failing antibiotics.
One approach to new anti-infectives is to create drugs that
render microbes vulnerable to host clearance mechanisms such as
innate immunity without being directly detrimental to the target
organism. Multiple innate defense mechanisms are thought to
participate in clearance of bacteria from the urinary tract. A robust
pro-inflammatory cytokine response of IL-6 and IL-8 results from
TLR4-LPS stimulation [12,13,14,15]. Subsequently neutrophils
are recruited into the urinary tract, producing pyuria. Comple-
ment levels increase during inflammatory conditions in the urinary
tract [16] and may be an important mechanism of defense.
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peptides called defesins, are abundant in the urine [17]. AP form
pores in phospholipid bilayers but require access to the bacterial
outer membrane for function [18]. The effectiveness of the innate
immune response against bacteria such as E. coli may, however,
may be hindered by bacterial factors such polysaccharide capsules.
E. coli is also a well-recognized cause of urosepsis, and bacteria
translocating from the urinary tract into the bloodstream are
subject to most of these same assaults as enacted by the innate
immune system of the urinary tract.
Capsules are well-established virulence factors for a variety of
pathogens and serve to protect the cell from opsonophagocytosis
and complement-mediated killing (reviewed in [19,20]). K
capsules, also called K antigens, are enveloping structures
composed of acidic, high-molecular-weight polysaccharides.
Among UPEC, the K antigens K1, K5, K30, and K92 are most
prevalent [21]. In recent work, Llobet et al. demonstrated that
highly acidic polysaccharide capsules of K. pneumoniae, P. aeruginosa,
and S. pneumoniae interact strongly with APs, acting as ‘‘sponges’’ to
sequester and neutralize the APs [22]. Furthermore, we have
found that K capsule contributes to multiple aspects of UTI
pathogenesis, including intracellular replication [23], making
inhibition of capsule biosynthesis a novel target for attenuation
of UPEC virulence.
The Group 2 K capsule genes can be divided into three genetic
regions: ASSEMBLY (I), SYNTHESIS (II), and EXPORT (III).
Group 2 & 3 capsules require homologous ASSEMBLY and
EXPORT proteins, but the genes for Group 3 are re-distributed
among the Region I-III gene clusters. In addition, many of the
components encoded in Regions I and III have homologues in
other medically important bacteria such as Neisseria meningitidis, and
these counterparts also participate in capsule biogenesis. Among
the E. coli Group 2 capsules, the K1 and K5 serotypes account for
the majority of UPEC K clinical isolates. K1 is composed of a2,8
linked poly-Neu5Ac, and K5 contains repeating N-acetylglucosa-
mine and glucuronic acid units [24,25].
Genetic disruption of Group 2 and Group 3 capsule production
results in predictable phenotypes, and determining if and where
polysaccharide accumulates in the cell can point to where capsule
biogenesis is blocked by genetic mutation or chemical inhibition.
Interruption of many points in the SYNTHESIS genes abrogates
the accumulation of intra- and extracellular polymers and renders
the organism insensitive to K1F phage, which requires surface
capsule for entry [26,27].
Inhibiting K capsule production may sensitize the organism to a
conventional antibiotic or component of the immune system.
Proof-of-concept evidence comes from the demonstration that
injection of purified K1 endosialiase prevented sepsis and
meningitis after intraperitoneal infection of neonatal rats with E.
coli K1 [28]. Endosialidase had no direct in vitro effect on E. coli K1
viability, but presumably removed K1 capsule in vivo, rendering
the organism more susceptible to host immune factors and
external stress, attenuating the infection. However, endosialidases
have limited therapeutic applications due to their antigenicity,
poor bioavailability, and potential action on sialidated host
proteins and lipids with shared linkages as the capsular sialic acids
[such as those present in neural tissues, reviewed in [29]].
Furthermore, endosialidase has a very narrow biochemical target
range, limiting its application to specific K antigen types.
Chemical inhibition of K capsule production may achieve similar
therapeutic results without most of these limitations.
Exploiting the properties of K capsule-specific phage, we
designed an innovative yet simple screen to uncover small
molecule inhibitors of capsule biogenesis. In this report, we
highlight the potential of our approach by describing the
identification and basic characterization of a novel agent
designated ‘‘C7’’. This agent is active (IC50 between 12.5–
25 mM), blocks the production of K1 and K5 capsule biogenesis
and lacks obvious toxicity to cultured bladder epithelial cells.
Beyond the scope of C7 and its analogues as potential capsule
inhibitors, the knowledge gained through these studies will
expedite future large screens for additional broad spectrum
capsule inhibitors, elucidation of their molecular targets, and
evaluation as anti-therapeutics.
Results
High-throughput screen for small compound inhibitors
of capsule
Based on the conservation between the assembly and export
components of Group 2 capsule biogenesis (shown in Figure 1A),
we hypothesized that chemical inhibitors of multiple K type
capsules could be identified. A high-throughput screen for
inhibitors of encapsulation was developed in which the prototypic
uropathogenic Escherichia coli strain UTI89 was grown in LB broth
in 96-well plates in the presence of 100 mM compound or 1%
DMSO vehicle followed by treatment with the K1 capsule specific
phage K1F (K1F w). Figure 1B depicts the screening process.
A wild-type UTI89 K1 encapsulated strain grown in the
presence of vehicle and treated with K1F phage at an
OD600<0.1–0.2 was quickly lysed and served as a positive control.
In contrast, a genetic capsule assembly mutant (UTI89 DkpsM) was
resistant to K1F phage lysis and was used as a negative control.
Compounds that affected capsule synthesis or assembly were
predicted to produce bacterial resistance to phage. A large signal-
to-noise ratio and low frequency of false positives make this a very
robust assay. The Z’ factor, a measurement of the suitability of a
particular assay for use in a full-scale high-throughput screen, was
determined to be 0.93 when performed in a 96 well microtiter
plate format.
We expected one of multiple outcomes from the assay. First,
chemical inhibitors of bacterial growth were expected to be
present in most chemical libraries. An initial absorbance reading
after ,1 hr of growth was used to determine those compounds
that severely affected bacterial growth (arbitrarily defined as those
with an OD600 less or equal to 0.05 after first time point and no
increase thereafter). Compounds producing growth inhibition
were not further analyzed. Of the compounds that did not inhibit
bacterial growth but prevented phage lysis, we anticipated they
would be categorized into two primary groups: 1) those affecting
capsule biogenesis (true positive) and 2) those inhibiting the phage
lifecycle (false positive). The later groups could be identified and
eliminated by the secondary screen described later.
In total, 2,195 compounds from the Developmental Therapeu-
tics Program at the National Cancer Institute were screened.
Seventy five (3.41%) of the compounds produced significant
inhibition of growth and were eliminated. Thirty five (1.59%)
compounds inhibited K1F phage lysis in the 96 well plate format.
However, only 9 of these 35 reproducibly inhibited phage lysis in a
larger shaken tube format and these 9 were advanced into the
secondary screening process. Table 1 summarizes the results of the
initial high-throughput screen.
Secondary assays
Compounds that inhibited K1F phage lysis in the primary assay
were further tested in secondary screens to distinguish between
inhibition of capsule biogenesis and inhibition of phage replica-
tion. The secondary screens capitalize on the knowledge that T7
Chemical Inhibitors of Capsule
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[27]. However, K1F phage entry requires K1 capsule, while T7
phage entry is inhibited by the capsule. As a result, only
unencapsulated bacteria are subject to T7 infection and lysis [30].
The engineered K12:K1 hybrid strain called EV36 producing
K1 capsule was grown in the presence of the putative capsule
inhibitors and was then infected with T7 phage (T7w).
Compounds that sensitized the K12:K1 strain to T7 phage
were deemed to affect capsule, and 2 of 9 compounds rendered
EV36 sensitive to T7. The confirmation that these 2 compounds
were effective in eliminating capsule in this well-characterized
K1 hybrid strain is that it confirmed the capsule inhibition
e f f e c t si na ni n d e p e n d e n tu n related genetic background
(Table 1).
Figure 1. Group 2 capsules and overview of screening strategy to identify capsule biogenesis inhibitors. (A) Organization of the
genomic region encoding for major K capsule synthesis and assembly products. The Group 2 capsules are encoded from similar loci. The SYNTHESIS
gene products derive the primary monosaccharides necessary for capsule and render the monosaccharides competent for polymerization. The
ASSEMBLY and EXPORT products co-assemble to polymerize the capsule and transport it out of the bacterium where it envelops the cell. As
examples, K1 and K5 capsules differ in Region II gene number and identity. Interconnecting lines indicate degree of amino acid identity between key
structural components of capsule biogenesis encoded from Region I and Region III. Thick, thin, and doted lines indicate .97%, .94%, and .70%
identity, respectively (further details in Table S1). (B) Diagram of high-throughput screen for capsule inhibitors. Wells of a 96-well plate were seeded
with a dilution of UPEC K1 strain UTI89. Compounds from the DTP small molecule library were placed in appropriate wells at a final concentration
100 mM. After a short incubation, the K1 capsule specific K1F phage was added to these wells. Growth was monitored and compounds that did not
produce an initial growth inhibition but did inhibit phage lysis, suggesting altered capsule biosynthesis or phage inhibition, were further tested.
Secondary assays (indicated by shaded block) were conducted using the engineered K-12:K1 strain EV36. T7 phage, inhibited by T7 capsule but
genetically similar to K1F phage, was used to infect this strain. Compounds that sensitized cells to T7 phage were classified as having capsule-specific
effect(s) and selected for further analysis. Finally, the K-12 strain MG1655, which is readily lysed by T7 phage, was used in a final assay to determine
which compounds inhibited phage lysis.
doi:10.1371/journal.pone.0011642.g001
Table 1. Summary of high-throughput screen.
N%
Total compounds screened 2195 -
Compounds causing growth inhibition 75/2195 3.42
Inhibited K1 lysis 35/2195 1.59
Sensitized K-12:K1 to T7 phage 2/9 0.09
Inhibited T7 lysis of K-12 strain 7/9 0.32
doi:10.1371/journal.pone.0011642.t001
Chemical Inhibitors of Capsule
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due to inhibition of phage replication, the prototypic K-12 strain
MG1655, which lacks K1 capsule and is readily susceptible to T7
phage infection, was grown in the respective compounds.
Compounds inhibiting T7-mediated lysis of MG1655 were
excluded as being phage-specific and not affecting capsule
biogenesis. Several compounds inhibited T7 lysis of MG1655,
indicating that they likely affected phage physiology (Table 1).
Table 2 lists the agents that passed the primary screen and
indicates the performance of each chemical in the secondary
assays.
C7 as lead compound
In our initial screen, we identified 2 inhibitors of capsule
biogenesis (Table 2). Although not previously described as an
inhibitor of capsule biogenesis, NSC5550, also known as
malachite green oxalate, produces metabolites with known
toxicities to mammalian systems and was therefore not pursued
further at this time. The other inhibitor, 2-(4-phenylphenyl)-
benzo[g]quinoline-4-carboxylic acid (NSC136469), was investi-
gated further. We designated this molecule as ‘‘C7’’ and
pursued it as a prototype for a chemical inhibitor of capsule
biogenesis. C7 reproducibly inhibited K1F phage lysis of UPEC
K1 strain UTI89 in tests following the high throughput screen
(Figure 2A), and the inhibition was found to be dose-dependent
with the effect reaching saturation at ,25 mM C7 (p=0.3731
25 mMa n d1 0 0mM C7), producing ,50% inhibition of K1F
phage lysis of UPEC at 12.5–25 mM (Figure 2A). C7 activity was
also tested on the K12:K1 strain EV36, a reciprocal experiment
of the K1F lysis inhibition. EV36 grown in the presence of
100 mMC 7w a sh i g h l ys u s c e p t i b l et oT 7p h a g e ,s u g g e s t i n gt h a t
C7 inhibited K1 capsule production and allowed T7 to attach,
enter, and lyse the target bacteria (Figure 2B). Next, we
determined if C7 could inhibit a distinct non-K1 Group 2 K
capsule-expressing strain. The UPEC K5 pyelonephritis isolate
D S 1 7w a sg r o w ni nt h ep r e s e n c ea n da b s e n c eo fC 7 .W i t h o u t
C7, DS17 was readily lysed by K5 bacteriophage. In contrast,
treatment with 100 mM C7 nearly completely inhibited K5
bacteriophage lysis (Figure 2C). In summary, the phage data
suggests that C7 acts also on K5 capsule production/assembly
and that C7 targets a convergent point in the production of
t h e s et w od i f f e r e n tG r o u p2p o l y s a c c h a r i d ec a p s u l e s .T h e s ed a t a
provide proof-of-principle that this simple and efficient high-
throughput screen of a relatively limited compound library is
able to yield candidate small molecule inhibitors of Group 2
capsule biogenesis.
Effect of C7 on capsule
Based on the results of our phage assays, we hypothesized that
C7 acts on a step in capsule assembly or export that is common to
both K1 and K5 capsule types. In order to localize the point of
inhibition and the molecular target of C7, we sought to determine
the phenotypic consequences of C7 treatment on capsule
biogenesis, and whether C7 treatment resulted in capsule release,
intracellular accumulation of polymer, or inhibition of synthesis.
Whole cells and sonicates were used in agglutination and radial
immunodiffusion assays using the H46 anti-K1 capsule polyclonal
antiserum. Whereas wild-type and genetic capsule synthesis
mutants were positive and negative for agglutination, respectively,
C7 treated UTI89 did not agglutinate, and whole cell sonicates
had only weak reactivity (Table 3). We next sought biochemical
evidence that C7 inhibited capsule production in UPEC K1.
Extracted polysaccharides obtained from whole cell sonicates or
surface capsule released (by mild acid treatment (adapted from
[31]), were treated with Bial’s orcinol reagent that reacts with
pentoses [32]. Polysaccharides extracted from whole cell sonicates
of C7 treated cells yielded significantly lower orcinol reactivity
than extracts from untreated cells (p,0.01), but without statistical
differences in reactivity compared to extracts from a genetic
SYNTHESIS mutant (Figure 3A). Consistent with the whole cell
data, acid-released polysaccharides from C7 treated cells also had
low orcinol reactivity, statistically no different than a SYNTHESIS
mutant (UTI89 Dneu; Figure 3B). We tested if C7-treatment
resulted in spontaneous release of polysaccharide into the media
without proper anchoring into the outer membrane. LPS
alterations have previously been shown to affect encapsulation
[33]. However, concentrated ultrafiltrates of culture supernatants
from C7-treated bacteria did not produce agglutination with
antibody (data not shown). Furthermore, C7 treatment did not
affect LPS abundance or migration on SDS PAGE gels (Figure S1;
method described in Materials and References S1), indicating that
lack of phage sensitivity and other phenotypes associated with C7
treatment are not due to defects in LPS. Together, these results
suggest that C7 may be blocking an early step in capsule assembly,
since weak agglutination and orcinol reactivity of whole cell
sonicates of C7-treated cells indicates little to no intracellular
accumulation of capsule and there was no detectable release of
capsule upon acid treatment.
Whole cells and sonicates were used in agglutination and radial
immuno diffusion assays using the H46 anti-K1 capsule polyclonal
antiserum. Whereas wild-type and capsule synthesis mutants were
positive and negative for agglutination, respectively, C7 treated
UTI89 did not agglutinate and whole cell sonicates had only weak
reactivity.We predicted that an inhibitor of K1 and K5 capsule
production was unlikely to target monosaccharide synthesis since
the compositions of the K1 and K5 capsules are different, thus
lacking an obvious central target of inhibition in early synthesis
shared between both types. To confirm that C7 did not inhibit
sialic acid synthesis and thus K1 capsule production, cultures were
grown in the presence of up to 500 mM of N-acetyl neuraminic
acid (NANA; sialic acid). However, this supplementation to the
medium did not restore sensitivity of C7 treated strains to K1F
phage lysis, suggesting that K1 capsule was not produced (data not
shown). These data suggest that inhibition is not directly on the
components of the synthesis pathway, since prior studies have
shown that defects in NeuB or NeuC, critical synthesis enzymes
encoded in Region II (Figure 1A), can be corrected by addition of
exogenous precursor sialic acid [34,35].
Table 2. Summary of capsule-specific and phage specific
effects of selected lead compounds.
NSC
number
K1F phage
inhibition
EV36/T7
phage lysis
MG/T7
phage lysis Interpretation
35605 Yes No No Phage specific
13028 Yes No Yes Phage specific
136469 (C7) Yes Yes Yes Capsule specific
5550 Yes Yes Yes Capsule specific
5159 Yes No Not for 2 hr Phage specific
661755 Yes No Not for 2 hr Phage specific
322921 Yes No No Phage specific
311153 Yes No Not for 2 hr Phage specific
311152 Yes No Not for 3 hr Phage specific
doi:10.1371/journal.pone.0011642.t002
Chemical Inhibitors of Capsule
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In order to gain more insights into the important structural
elements of C7, we also tested a limited series of structurally
related compounds for inhibition of K1F phage lysis (Figure S2);
however, none of the compounds tested was highly active.
NSC201538 (2-(4-dimethylaminophenyl)benzo[g]quinoline-4-car-
boxylic acid) had limited activity, where the major substitution
differentiating it from C7 was in the 4-dimethylaminophenyl
substitution in place of the 4-phenyl-phenyl group present in C7,
demonstrating the importance of the specific R-group for C7
activity.
Treatment increases C3 binding to UPEC K1 and serum
sensitivity
As noted previously, polysaccharide capsules have known
inhibition effects on complement binding to bacteria. We
hypothesized that C7 treatment of UPEC K1 would result in
increased binding by complement C3, initiating recruitment of the
complement attack complex. UPEC K1 was treated with C7 or
vehicle control and then incubated in normal human serum. C7
treatment produced a significant increase in C3 binding to the
treated bacteria (,2-fold, Figure 4). These data suggest that C7
treatment renders the cells more susceptible to C3 binding, which
in turn is known (specifically through C3b) to promote formation
of the MAC complex and phagocytosis.
Given the increased binding of C3 to C7-treated cells, we
anticipated that the chemically treated cells would have
increased serum sensitivity similar to a genetic capsule mutant.
Because of the established role of capsule in resistance by E. coli
to serum killing, chemical capsule inhibition would be expected
to sensitize encapsulated strains to serum exposure, thus
attenuating infection and providing a useful therapeutic
intervention. We tested whether exposure of the K1 encapsu-
lated strain UTI89 to C7 increased its sensitivity to human
serum in an in vitro assay with pooled human serum. After a
2 hour exposure of 10
3 CFU to 20% normal active human
serum resulted, 35% of UPEC K1 remained viable. In contrast,
the same serum exposure resulted in complete killing of the
SYNTHESIS mutant (Figure 5). C7 treatment (100 mM) of
UPEC K1 followed by the same serum exposure resulted in
,1% of the bacteria remaining viable, statistically the same as
for the genetic capsule mutant (no significant difference by
Tukey’s Multiple Comparison Test). C7 treatment rendered the
cells significantly more serum sensitive than untreated wild type
(p,0.001). These results illustrate the potential of capsule
biogenesis inhibitors to increase the susceptibility of UPEC to
t h ei n n a t ei m m u n er e s p o n s e .
C7 is active on clinical E. coli isolates
To demonstrate that the effect of C7 is not limited to the
prototypic laboratory UPEC strain UTI89, capsule inhibition by
C7 was tested on a panel of clinical E. coli K1 isolates in the K1F
phage sensitivity assay. These strains encompass isolates from
pyelonephritis (4), recurrent UTIs (3), and single UTI cases (1). As
seen in Figure 6, the majority of phage-sensitive isolates tested
responded to C7 treatment by becoming insensitive to K1F phage,
thus suggesting that capsule production was inhibited by the
addition of C7 in these isolates, similar to the situation with strain
UTI89. Two strains responded to C7 with only partial insensitivity
to K1F, suggesting incomplete inhibition of capsule biogenesis.
These results support the idea that C7 is active on a range of
clinically relevant strains causing UTIs.
Figure 2. C7 inhibition of K1 and K5 capsule dependent phage lysis. (A) C7 inhibits K1 capsule-dependent phage lysis of UPEC. UPEC K1
strain UTI89 was grown in the presence of 1% DMSO or indicated concentrations of C7 for 1 hr and K1F phage was added where indicated. Relative
OD600 change after 4 hrs is shown. Increasing C7 concentrations inhibit lysis of UPEC K1. P value: ,0.0001 No C7 (0 mM) compared to each of C7
treatments .12.5 mM. (B) C7 sensitizes K12:K1 strain to T7 phage. The K12 strain EV36 producing K1 capsule was infected with T7 phage (T7w), which
is inhibited by the presence of K1 capsule. Addition of 100 mM C7 sensitized EV36 to T7 phage (p=,0.0001). (C) C7 inhibits K5 capsule-dependent
phage lysis. UPEC K5 strain DS17 was incubated with (K5w) or without phage and relative change in OD600 was recorded. Addition of 100 mMC 7
prevented lysis by K5 capsule specific phage (p,0.0001).
doi:10.1371/journal.pone.0011642.g002
Table 3. Summary of agglutination assays.
Strain Whole cell sonicates
Radial
immunodiffusion assay
K1 ++
K1 synthesis 22
K1+100 mM C7 weak 2
Whole cells and sonicates were used in agglutination and radial immuno
diffusion assays using the H46 anti-K1 capsule polyclonal antiserum. Whereas
wild-type and capsule synthesis mutants were positive and negative for
agglutination, respectively, C7 treated UTI89 did not agglutinate and whole cell
sonicates had only weak reactivity.
doi:10.1371/journal.pone.0011642.t003
Chemical Inhibitors of Capsule
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To further assess the therapeutic potential of C7, we next
examined the potential toxicity of C7 using a widely used LDH
release assay after treatment of the bladder epithelial cell line 5637
at several C7 concentrations up to 100 mM( .4-fold over the
IC50), as compared to 1% DMSO vehicle. No significant increase
in LDH was measured at the maximum tested concentration of C7
compared to the vehicle control (Figure S3; methods described in
Materials and References S1).
Discussion
E. coli is by-far the leading cause of community-acquired UTIs.
On an annual basis, over 100 million UTIs occur throughout the
Figure 4. C7 increases C3 binding to UPEC K1. UTI89 was
incubated with human serum and C3 binding was quantified by
densitometry of immuno-dot blot. C7 treatment increases C3 binding to
levels similar to an unencapsulated cell (K1 SYNTHESIS mutant;
p=0.0054).
doi:10.1371/journal.pone.0011642.g004
Figure 5. C7 sensitizes K1 encapsulated UPEC to human serum.
Three ml cultures of the K1 encapsulated UPEC strain UTI89, a capsule
synthesis mutant (K1 SYNTHESIS), and wild-type cells treated with
100 mM C7 were grown in LB +1% DMSO or C7 for ,3 hrs with shaking
until reaching an OD600 of 0.8. Human serum from at least two
individuals was heat inactivated (HIS) at 55uC for 45 min or maintained
on ice (Normal Serum, NS). Bacterial cells were resuspended in PBS,
diluted to 5–9610
3 and incubated in RPMI/20% serum supplemented
with 1% DMSO or 100 mMC 7a t3 7 uC for 2.0 hrs. Duplicate independent
cultures for each strain were tested and the ratio of NS/HIS CFU/ml is
shown. The graph represents the average of two experiments.
doi:10.1371/journal.pone.0011642.g005
Figure 3. C7 treated cells produce less orcinol-reactive carbohydrates. Cells were (A) sonicated or (B) treated with mild acid to release cell
surface polysaccharides. Material was then extracted and polysaccharides were detected using the orcinol reagent. C7 treated cells had levels of
orcinol-reactive carbohydrates comparable to those of a capsule synthesis (K1 SYNTHESIS) mutant for both whole cell sonicates as well as released
surface material. This suggests that capsule levels are reduced by C7 treatment, and the compound does not simply release capsule from the
bacterial surface. Absorbance readings were expressed as the percent reactivity of the wild-type UTI89 K1 strain. K1 vs. SYNTHESIS mutant or C7
treated, p,0.01; SYNTHESIS mutant vs. C7 treated p.0.05 by Tukey’s t-test for both (A) and (B).
doi:10.1371/journal.pone.0011642.g003
Chemical Inhibitors of Capsule
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data, [2]). Rising resistance rates have threatened the arsenal of
antibiotics available for the treatment of community-acquired
UTI. New therapeutics for UTI are in great demand. The most
desirable chemotherapeutics may be those that attenuate an
organism during an infection without altering commensal
populations, so called anti-virulence agents [36,37].
UTI involved UPEC cycling between extracellular and
intracellular environments. Bacteria initially adhere to the bladder
epithelium, following which they may invade the epithelium, and
in some cases, escape into the cytosol of the infected epithelial cells
and amass into intracellular bacterial communities (IBCs). IBC
confer resistance to infiltration by neutrophils [38,39] and may
similarly reduce susceptibility to antibiotic therapy [40]. Intracel-
lular bacteria can emerge from IBCs and cAMP-regulated
exocytic vesicles and reinitiate adherence and invasion events
[41,42]. Early in the infection, TLR4 stimulation by LPS [43]
results in a strong inflammatory response, neutrophil recruitment,
and elaboration of antimicrobial peptides [44,45]. K capsule is
important for UPEC survival in the urinary tract, promoting
virulence at multiple steps of pathogenesis, including extracellular
and intracellular stages of infection [46]. We recently demonstrat-
ed a novel role for the intracellular expression of a polysaccharide
capsule as an aggregating factor in IBC formation [46]. Thus,
inhibitors of K capsule biogenesis may attenuate the bacterium at
multiple stages of infection.
Of the K type capsules, Groups 2 and 3 are overrepresented
among the extraintestinal pathogenic E. coli including UTI,
bloodstream and meningitis isolates. These capsular groups are
uncommon among commensal E. coli, and therefore, it may be
possible to selectively target the pathogenic organisms, particularly
during active infection, while leaving commensal organisms unper-
turbed. In addition to avoiding dysbioses such as antibiotic-induced
diarrhea caused by non-specific anti-microbial agents, anti-infectives
that do not stress commensal microbial reservoirs may also lessen the
emergence of drug resistance. Key components of the assembly and
export of Group 2 and Group 3 capsules are highly conserved (such
as KpsD, KpsC, KpsU, KpsS, and KpsM), making it theoretically
possible to identify small molecules that are capable of inhibiting the
biogenesis of a variety of capsules that differ significantly in
composition and antigenicity. However, many of these same
components are not well conserved among the other capsular types
more commonly expressed by commensal strains.
By exploiting the features of capsule-specific phage, we devised
an innovative, yet simple screen for small molecule inhibitors of K
capsule biogenesis. To demonstrate the throughput and efficiency
of the primary and secondary screens to identify capsule biogenesis
inhibitors and eliminate false positive hits, we applied the
screening procedure to a small collection of molecule libraries
and identified one agent designated as ‘‘C7’’ that inhibits the
production K1 and K5 capsules, unrelated polysaccharide types
among the Group 2 capsules. C7 rendered clinical isolates of K1
and K5 encapsulated UPEC resistant to capsule-specific phage,
decreased K1-antiserum agglutination, and shifted the carbohy-
drate profile of treated cells toward that of a genetic capsule
synthesis mutant. Of biological significance, treatment of E. coli
with C7 rendered the organism more susceptible to C3 binding
and serum killing, again mirroring the phenotype of an
unencapsulated genetic mutant. The IC50 of C7 between 12.5
and 25 mM suggests reasonable activity and a starting point for
additional workaround chemistry. The relative hydrophobicity of
C7 imposes some limitations on its potential distribution and
bioavailability if taken as a drug. Despite any potential limitations
of C7, our results provide proof-of-concept that the screening
algorithm may uncover additional novel small molecule inhibitors
of capsule biogenesis by applying the screen to libraries several
orders of magnitude larger in size.
In addition to their potential utility as therapeutic agents to
combat infections, chemical inhibitors of capsule biogenesis may
provide opportunities to further dissect the molecular processes
involved in capsule biogenesis. Our current biochemical and
immunological studies of the C7 effects on K1 capsule biogenesis
have localized the inhibition to an early stage of capsule
assembly, likely after sialic acid synthesis but prior to significant
oligimerization of the monosaccharides. Our studies excluded
other plausible mechanisms including alteration of LPS and
failure to anchor fully polymerized polysaccharide to the bacterial
surface. Additional studies will be required to improve our
understanding of the molecular mechanisms and targets behind
the action of C7. The genetic identity of the target of C7 would
provide a better understanding of the capsule biosynthesis process
and could greatly enhance the search for chemotherapeutics that
could target highly conserved components of the capsule
assembly machinery. This could lead to the attenuation of
diverse encapsulated organisms with commonalities in capsule
assembly. We anticipate that a large chemical library screen
Figure 6. C7 is active against other clinical K1 UPEC strains. A panel of K1F phage sensitive clinical E. coli strains was tested for phage
sensitivity in the presence or absence of 100 mM C7. Strains were grown in 1% DMSO or C7 and infected with K1F phage where indicated. Relative
OD600 change after 3 hrs post infection (normalized to the growth of UPEC strain UTI89) is shown. Addition of 100 mM C7 inhibits lysis of tested
clinical strains. P value: ,0.0001 no C7 (phage only) compared to C7 treatment. Arrow indicates two clinical strains in which C7 only partially restored
growth.
doi:10.1371/journal.pone.0011642.g006
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screens described in this work will yield a variety of active,
bioavailable, and synthetically amenable lead compounds to
further build on this technology.
Methods
Ethics statement
Normal human serum samples were obtained under a protocol
reviewed and approved by the Duke University Institutional
Review Board. The pooled serum used in these studies was de-
identified and anonymous.
Bacterial strains, phage, and growth conditions
All E. coli strains and phage used in the present study are listed
in Table 4. Clinical E. coli isolates were obtained from Dr. Walt
Stamm at the University of Washington. Unless indicated
otherwise, bacteria were routinely grown at 37uC in Luria-Bertani
medium (LB) with shaking at 250 rpm. Media were supplemented
with antibiotics as needed at the following final concentrations:
ampicillin, 100 mg/ml; chloramphenicol, 20 mg/ml; kanamycin,
50 mg/ml. LB was supplemented with 1% dimethyl sulfoxide
(DMSO; Acros) with or without compound. Phage lysates were
prepared from 5 ml cultures of UTI89 (for K1F phage), MG1655
(for T7 phage) or DS17 (for K5 phage) and stored at 4uC over
several drops of chloroform as described by [47].
Chemicals
Chemical compounds were obtained from the National Cancer
Institute’s Developmental Therapeutics Program (DTP). Com-
pounds were received in DMSO at a concentration of 10 mM and
stored at 220uC in small aliquots protected from light.
Screen to identify small molecular inhibitors of K1
capsule biogenesis in UPEC
Three ml overnight culture of K1 strain UTI89 grown in LB
was diluted 1:500, and 100 ml per well was added to a 96-well
plate (Whatman Uniplate). One microliter of each compound
from the DTP small molecule library was placed in appropriate
wells (final concentration 100 mM). The first and last columns of
the plates received DMSO vehicle alone and were used as
controls. Plates were sealed, shaken at 37uC for 2 hr, and the
OD600 was measured in a mQuant (BioTek) plate reader. Then,
30 ml of a K1F phage lysate was added to each well, except those
in the last column, which received LB alone. The plate was re-
sealed and shaken for an additional 2 hours before recording the
OD600 again (‘‘post-infection’’ measurements). Finally, plates
were resealed and shaken overnight for one last growth
measurement (‘‘late post-infection’’). Assays were repeated twice.
Compounds that did not inhibit growth of the test strain prior to
the addition of phage but did inhibit phage lysis were further
tested in phage assays in test tubes as putative capsule biogenesis
inhibitors. Z’ was calculated using a previously published
equation [48].
Capsule inhibition assay in test tubes
Overnight bacterial cultures were diluted 1:100 into three ml of
fresh LB supplemented with 100 mM of compound C7 or 1%
vehicle control (DMSO). Cultures were grown at 37uCt oa n
optical density OD600 of ,0.2 before addition of appropriate K1
capsule-specific phage or T7 phage (3 ml of lysate). Cultures were
incubated further, and growth was monitored by optical density.
The initial absorbance before infection was subtracted from the
reading at the indicated time point after infection. The log of the
absorbance values was then normalized to that of the culture with
no phage added, and relative change was plotted. The average of
triplicate replicates for a representative experiment was plotted
with standard deviations. Each experiment was repeated at least
twice with similar results to those shown.
K1 capsule agglutination assay
Three ml cultures were grown in the presence of 100 mM
compound or vehicle to an optical density of ,0.8, and cells were
harvested, washed with PBS, and resuspended in 0.5 ml of PBS.
Fiftymlo fc e l l sa n d5ml of undiluted H46 horse anti-Group B Neisseria
meningitidis capsule (antigenically identical to K1 capsule) polyclonal
antiserum [49] were combined, and agglutination was monitored.
This assay was repeated at least three times for each strain.
Radial immunodiffusion assay
PBS plates with 1% agarose were supplemented with 5% H46
antiserum. Cultures grown as for agglutination assays in the presence
of 100 mM compound or vehicle were extensively sonicated to
produce whole-cell lysates and added to wells created in plates (50 ml).
Plates were incubated upright at 30uC for 48–72 hrs and were
visually inspected for the formation of precipitin rings.
Orcinol reaction for carbohydrates
Three ml of cultures of the indicated strains were harvested at
OD600=0.8.Forwhole-cellorcinolmeasurements,cellswerewashed
once with PBS, resuspended in 1 ml of PBS, and sonicated. Five
hundred microliters of each sonicate were then extracted with
phenol:chloroform, and 100 ml was used for labeling. For released
material measurements, polysaccharides were separated from the
cells by mild acid release (Tris-acetate pH 5.0 for 2 hr with shaking)
followed by centrifugation to pellet the cells. Polysaccharides in the
cell-freesupernatantswerethende-proteinatedbyphenol:chloroform
extraction. The aqueous material was concentrated to 50 mlu s i n ga
YM-30 size exclusion filter.
For labeling, polysaccharides were then hydrolized with 0.1 M
HCl for 5 minutes at 90uCi n5 0ml of orcinol reagent [32]. Color
change was measured by absorbance and expressed as the percentage
of wild type levels. Each orcinol reaction was performed in duplicate
with independent cultures, and the entire assay was repeated at least
twice. A representative experiment is shown.
Table 4. Bacteria and phage used in study.
Strain/phage Description or relevant genotype Reference
Bacterial strains
UTI89 K1 Escherichia coli cystitis isolate [50]
UTI89 Dneu Region II K1 capsule synthesis mutant [46]
UTI89 DkpsM Region III K1 capsule assembly mutant This study
DS17 Escherichia coli K5 pyelonephritis isolate [51]
EV36 K12/K1 hybrid produced by conjugation
with an Hfr kps
+ strain; K1 encapsulated,
susceptible to K1 specific phage.
[52]
Phage
T7 phage (T7w) Inhibited by K1 capsule [30]
K1F phage (K1Fw) K1 capsule specific [26,27]
K5 phage (K5w) K5 capsule specific [53]
doi:10.1371/journal.pone.0011642.t004
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Human serum from at least two individuals was heat inactivated
(HIS) at 55uC for 45 min or was maintained on ice (normal serum,
NS). Cells were grown to OD600<1.0 and washed with PBS as
described for the agglutination assay. Cells were then pelleted at
80006g for 1 min and resuspended in DMEM (Sigma) +5% NS
or HIS and were incubated at 37uC for 15 minutes. Bacteria were
then pelleted and washed three times with PBS before resuspend-
ing in 500 ml of PBS. Three microliters were then spotted onto
nitrocellulose membranes and allowed to air dry overnight. The
membrane was blocked with 5% non-fat dry milk in TBS/0.1%
Tween 20 (TBS-T) for 2 hrs, rinsed with TBS-T two times for 15
minutes and exposed to the primary C3 antibody (1:10,000 in 1%
BSA/TBS-T, anti-human C3 developed in goat, from Sigma).
After washing two times with TBS-T, secondary anti-goat alkaline
phosphatase antibody was applied at a 1:10,000 dilution. The
immuno dot blot was developed using a colorimetric substrate
(ImmunoO; MP Biochemicals), and densitometry was performed
using Image J (NCBI) software.
Serum resistance assays
Overnight cultures of the indicated strains were diluted 1:100
into three ml of LB with 1% DMSO (final) or 100 mM C7.
Cultures were grown for ,3 hrs with shaking until reaching an
OD600 of 0.8. Bacterial cells were resuspended in PBS, diluted to
5–9610
3 CFU/ml and incubated in serum-free RPMI (Sigma)
supplemented with 20% human serum and 1% DMSO or
100 mM C7. Cells were incubated in RPMI/serum at 37uC for
2.0 hrs. Duplicate independent cultures for each strain were
tested, and the ratio of NS/HIS CFU/ml is shown. Experiments
were repeated at least two times.
Phage sensitivity assays for clinical E. coli strains
Clinical E. coli strains were screened for K1F and K5 phage
sensitivity in 96-well trays. Briefly, a panel of clinical fecal,
bloodstream, and urinary tract E. coli isolates from Walt Stamm at
the University of Washington was arrayed into a 96-well plate and
grown with vigorous shaking in LB in deep-well 96-well plates.
Cultures were then diluted 1:100 into 100 mlo fL Bw i t h1 %D M S O .
The plate was sealed with breathable tape and incubated at 37uC
with vigorous shaking for 2 hrs (OD600 ,0.1–0.2). Five microliters of
a high-titer phage lysate were then added to each well. Growth was
monitored spectrophotometrically every 1.5 hrs and ‘‘phage sensitive
strains’’ were determined to be those strains for which absorbance
decreasedafter3.0 hrsofincubation.Eachstrainwastestedinatleast
four independent plates. Isolates that were consistently lysed by
addition of phage were then used in subsequent experiments to
determine if addition of 100 mM C7 inhibited phage lysis using the
same 96-well plate format. Inhibition of phage lysis by C7 was
considered to be growth equivalent to uninfected parent strain after
3 hrs incubation post-infection, and this experiment was repeated at
least 4 times with similar results. Relative change in OD was
calculated as the log of the absorbance values and normalized to that
of strain UTI89 in the same assay. The average of three independent
cultures for each strain is shown.
Statistical analyses
Results were calculated as averages and standard deviations of
the means using the Graph Pad Prism 4 software package (San
Diego, CA). Nonparametric t-tests were used for statistical analysis
of data and calculation of p-values using Graph Pad Prism 4 or
Graph Pad online calculators. Significant differences were
highlighted with a single asterisk when the P value is less than
0.05, with two asterisks when the P value is less than 0.01, and
three asterisks when the P value is less than 0.001.
Supporting Information
Materials and References S1 Supplemental methods and
references.
Found at: doi:10.1371/journal.pone.0011642.s001 (0.04 MB
DOC)
Figure S1 C7 is non-toxic to bladder epithelial cells. LDH
release assay after incubation of 5637 cells with vehicle (1%
DMSO) or C7. Concentrations of C7 up to 100 mM did not
significantly affect LDH release compared to vehicle control.
Triton X detergent control represents maximum LDH release.
Found at: doi:10.1371/journal.pone.0011642.s002 (0.16 MB TIF)
Figure S2 C7 treatment does not affect LPS profile. No
significant difference was observed in LPS migration or accumu-
lation with and without C7 treatment (Lane 1 vs. 2). The figure
represents two independent gels with the same set of samples.
Found at: doi:10.1371/journal.pone.0011642.s003 (3.89 MB TIF)
Figure S3 Compounds similar to C7 do not inhibit K1 capsule-
dependent phage lysis. Panel A: Analogues of C7 tested as K1
capsule biogenesis inhibitors. Panel B: K1F phage sensitivity assays
with 100 mM C7 and analogues.
Found at: doi:10.1371/journal.pone.0011642.s004 (0.98 MB TIF)
Table S1 Similarity and identity of key proteins of group 2
capsule biogenesis in E. coli. UTI89 (K1, Group 2 capsule) proteins
were compared to other E. coli Group 2 capsule homologues and
minimum percent identity and similarity indicated. The Basic
Local Alignment Search Tool (BLAST, NCBI) was used to
compare key Group 2 capsule assembly proteins from the
prototypic K1 strain UTI89 with sequenced E. coli genomes
(taxonomic ID 562) with Group 2 capsule gene arrangement. The
following sequenced Escherichia coli genomes were considered in the
BLAST search: UTI89, SMS 3-5, ED1a, IAI39, APEC01, S88,
042, F11, SE15, BL21 (DE3), Nissle 1917, 101-1.
Found at: doi:10.1371/journal.pone.0011642.s005 (0.03 MB
DOC)
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